 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. Nasdaq: HGEN Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, announced that management will host a conference call and webcast today at 8am ET to discuss topline results from the Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19. Details for the upcoming conference are below: Webca 